Weekly View

ICER Weekly View 02-17-17

From the desk of Mitchell Stein   Good morning. In the week since we’ve talked, I’ve been buried both literally and figuratively. Here in Portland ME, we’ve had over 30 inches of snow this week, while nationally, the “news” just keeps on coming. To help with the volume, today I’ve divided our stories into four […]

Read More

ICER Weekly View 02-10-17

From the desk of Mitchell Stein   Good morning. Welcome to the new weekly version of this blog. To help navigate with the increased number of articles (although I promise, I’m trying not to go crazy), I’ve added subcategories to the Pharmaceutical News section. In addition to ICER in the News, today’s subsections include […]

Read More

Changes coming to Morning View

From the desk of Mitchell Stein   Starting this Friday, ICER Morning View will return in a new format, going from a daily brief on the news to a weekly review of top stories: The ICER Weekly View. I enjoy writing this combination blog and news digest, and over the past year, I’ve been humbled […]

Read More

Morning View 02-02-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. ICER announced proposed changes to our value assessment framework, links below to the announcement and some of the coverage. ICER was also mentioned in an opinion piece looking at possible improvements to current FDA processes. In Washington, Price’s nomination moved forward as […]

Read More

Morning View 02-01-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. We’ll start with ICER news as a Takeda executive discusses us in an interview, and we post this month’s edition of New and Noteworthy. On the industry front, once again we start in DC with two big stories, the first is the […]

Read More

Morning View 01-31-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. As with most days recently, we’ll start in Washington with an Executive Order regarding issuing new regulations. Also from inside the beltway Rep. Price faces more questions on his stock purchases, industry representatives will meet with the President today, and an in-depth […]

Read More

Morning View 01-30-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. While much of Washington (and the rest of the world) was focused on non-healthcare related actions of the administration, there are still healthcare stories to discuss. Rep. Price’s confirmation to lead HHS will face a Senate Finance Committee vote on Tuesday; Democratic […]

Read More

Morning View 01-27-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. Yesterday we released our Evidence Report on Multiple Sclerosis, see below and the website for more details on the report and upcoming CTAF meeting. NY Governor Cuomo’s proposal to reign in drug costs could have a role for ICER, Politico discusses. On […]

Read More

Morning View 01-26-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. With Washington focusing on other matters, we’ll take a break from “inside the beltway” talk and look at other topics. We’ll start off with a look at the $30 billion J&J purchase of Swiss biotech firm Actelion. We’ll also look at a new […]

Read More

Morning View 01-25-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. We’ll start today with political news: A new potential healthcare player for the administration, an interview with a potential FDA Commissioner, how the federal hiring freeze could impact the FDA, and a look at Price’s second confirmation hearing. On the industry front, […]

Read More

Sign-up to have the Weekly View delivered to your inbox every Friday morning.

SIGN UP